© 2022 MJH Life Sciences and Managed Healthcare Executive. All rights reserved.
© 2022 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
May 06, 2022
Drs Al-Hendy and Lopes conclude with final thoughts on GnRH receptor antagonists, relugolix and elagolix, changing the UF treatment landscape.
Dr Al-Hendy discusses what it takes to individualize UF treatment for each patient.
April 29, 2022
Drs Lopes and Al-Hendy describe the unmet needs they see when treating patients with UF.
Dr Maria Lopes provides an overview of common disparities seen when treating and maintaining women’s reproductive health and how these can be minimized.
April 22, 2022
Dr Lopes discusses the typical payer challenges with managing UF treatment, including pain management.
Dr Al-Hendy highlights the oral GnRH receptor antagonists as first-line therapy for UF.
April 18, 2022
Dr Al-Hendy briefly explains how he determines treatment goals during initial workups for patients with UF.
Dr Ayman Al-Hendy details the shift from surgical options to medical therapy for patients with UF.
April 08, 2022
Ayman Al-Hendy, MD, PhD, FRCSC, FACOG, CCRP, elaborates on risk factors for the development of UF.
Maria Lopes, MD, discusses the economic burden of UF from a payer’s perspective, explaining direct and indirect costs associated with the condition.